Mycophenolate mofetil in primary central nervous system vasculitis

Carlo Salvarani, Robert D. Brown, Teresa J H Christianson, John Huston, Caterina Giannini, Dylan V. Miller, Francesco Muratore, Gene G. Hunder

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalSeminars in Arthritis and Rheumatism
Volume45
Issue number1
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Central Nervous System Vasculitis
Mycophenolic Acid
Therapeutics
Leukopenia
Prednisone
Cyclophosphamide
Safety
Recurrence

Keywords

  • Mycophenolate mofetil
  • PCNSV
  • Therapy
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

Salvarani, C., Brown, R. D., Christianson, T. J. H., Huston, J., Giannini, C., Miller, D. V., ... Hunder, G. G. (2015). Mycophenolate mofetil in primary central nervous system vasculitis. Seminars in Arthritis and Rheumatism, 45(1), 55-59. https://doi.org/10.1016/j.semarthrit.2015.02.008

Mycophenolate mofetil in primary central nervous system vasculitis. / Salvarani, Carlo; Brown, Robert D.; Christianson, Teresa J H; Huston, John; Giannini, Caterina; Miller, Dylan V.; Muratore, Francesco; Hunder, Gene G.

In: Seminars in Arthritis and Rheumatism, Vol. 45, No. 1, 01.08.2015, p. 55-59.

Research output: Contribution to journalArticle

Salvarani, C, Brown, RD, Christianson, TJH, Huston, J, Giannini, C, Miller, DV, Muratore, F & Hunder, GG 2015, 'Mycophenolate mofetil in primary central nervous system vasculitis', Seminars in Arthritis and Rheumatism, vol. 45, no. 1, pp. 55-59. https://doi.org/10.1016/j.semarthrit.2015.02.008
Salvarani, Carlo ; Brown, Robert D. ; Christianson, Teresa J H ; Huston, John ; Giannini, Caterina ; Miller, Dylan V. ; Muratore, Francesco ; Hunder, Gene G. / Mycophenolate mofetil in primary central nervous system vasculitis. In: Seminars in Arthritis and Rheumatism. 2015 ; Vol. 45, No. 1. pp. 55-59.
@article{9231d910f3a4435e840992a0e2c2b47f,
title = "Mycophenolate mofetil in primary central nervous system vasculitis",
abstract = "Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.",
keywords = "Mycophenolate mofetil, PCNSV, Therapy, Vasculitis",
author = "Carlo Salvarani and Brown, {Robert D.} and Christianson, {Teresa J H} and John Huston and Caterina Giannini and Miller, {Dylan V.} and Francesco Muratore and Hunder, {Gene G.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.semarthrit.2015.02.008",
language = "English",
volume = "45",
pages = "55--59",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Mycophenolate mofetil in primary central nervous system vasculitis

AU - Salvarani, Carlo

AU - Brown, Robert D.

AU - Christianson, Teresa J H

AU - Huston, John

AU - Giannini, Caterina

AU - Miller, Dylan V.

AU - Muratore, Francesco

AU - Hunder, Gene G.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

AB - Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

KW - Mycophenolate mofetil

KW - PCNSV

KW - Therapy

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84937737529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937737529&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2015.02.008

DO - 10.1016/j.semarthrit.2015.02.008

M3 - Article

C2 - 25800827

AN - SCOPUS:84937737529

VL - 45

SP - 55

EP - 59

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 1

ER -